Treatment Discontinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 Inhibitors or NPH Insulin as Third-Line Therapy

<div>Kaplan-Meier curves for discontinuation of therapy (prescription gap &gt; 90 days) in type 2 diabetes mellitus patients initiating NPH insulin or DPP-4 inhibitors, 2011–2014.</div>

Journal of Diabetes Research

fig2

Figure 2

Figure 2: Treatment Discontinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 Inhibitors or NPH Insulin as Third-Line Therapy 

Figure 2 | Treatment Discontinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 Inhibitors or NPH Insulin as Third-Line Therapy 